#Japan #oncology #Tokyo #UBE #Zeureka

ZeuReka and UBE Collaborate on Cancer Research

ZeuReka, a Tokyo-based pharmaceutical technology company, has recently entered into a collaborative research agreement with UBE Corporation, aimed at advancing low-molecule drug discovery specifically for cancer treatment. This partnership marks a significant step towards developing innovative therapeutic solutions in oncology.

Utilizing Advanced Computational Techniques

ZeuReka's expertise lies in its proprietary computational drug design technology. One of their standout tools, the Free Energy Perturbation (FEP) program, is engineered to enhance the potency and accuracy of drug discovery processes. By applying this high-caliber computational technology, the collaboration intends to identify new low-molecule compounds targeting specific cancer-related molecules that UBE has identified as promising for therapeutic use.

This initiative commenced after both companies validated the applicability and accuracy of the Xeureka FEP program concerning the identified research targets. Following successful assessments, they were able to align their objectives and formally launch their joint research efforts.

Financial Implications of the Agreement

This newly inked agreement provides ZeuReka with some initial financial benefits, including a signing bonus and the right to receive milestone payments in relation to the advancement of their research. Such financial arrangements underscore the commitment of both parties to creating impactful solutions within the oncology landscape.

About ZeuReka: Innovation at Its Core

Founded in November 2021, ZeuReka is dedicated to providing cutting-edge drug discovery support services utilizing extensive computational resources including large-scale supercomputers. The company specializes in a variety of innovative molecular dynamics simulations and artificial intelligence tools to cater to the evolving needs of pharmaceutical and biotech firms. With an aim to streamline research processes and significantly increase success rates in drug development, ZeuReka continues to enhance its offerings through high-precision predictive modeling and expansive virtual screening capabilities.

Company Overview

• - Location: 3-2-2 Toranomon, Minato-ku, Tokyo, Japan
• - CEO: Taisei Nagae
• - Founded: November 2021
• - Shareholder: Mitsui & Co., Ltd. (100%)
• - Services: AI drug discovery support, computational environments, and collaborative research development.

For more information, visit: ZeuReka Official Site

UBE Corporation: Commitment to Life Sciences

Established in March 1942, UBE Corporation is at the forefront of specialty chemicals with a keen focus on life sciences. Their pharmaceutical division is pivotal, seeking to transcend traditional low-molecule drugs with innovative approaches such as Antibody-Drug Conjugates (ADCs). Additionally, UBE is expanding its Contract Development and Manufacturing Organization (CDMO) activities to not only bolster existing low-molecule drug capabilities but also enhance production techniques for next-generation modalities like nucleic acid medicines, contributing to public health and wellbeing.

Company Overview

• - Location: 1-2-1 Shibaura, Minato-ku, Tokyo, Japan
• - CEO: Yuki Nishida
• - Founded: March 1942
• - Services: Manufacturing and sales of chemicals and machinery.

For further inquiries, visit: UBE Corporation Official Site

In conclusion, the partnership between ZeuReka and UBE stands as a pivotal development in the oncology research domain. By combining advanced computational technologies and targeted research efforts, both companies aspire to make significant contributions to the fight against cancer, potentially changing the landscape of cancer treatment products in the near future.